Home > News > 52/First-in-man use of fusion-based multisite left ventricular pacing utilising a leadless endocardial cardiac resynchronisation therapy system (WISE-CRT)
Arrhythmia
Read Time: 2 mins

52/First-in-man use of fusion-based multisite left ventricular pacing utilising a leadless endocardial cardiac resynchronisation therapy system (WISE-CRT)

Published Online: September 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr52
Authors: C Monteiro (Presenting Author) - University of Oxford, Oxford; D Webster - Oxford University Hospitals NHS Foundation Trust, Oxford; J Ormerod - Oxford University Hospitals NHS Foundation Trust, Oxford; T Betts - Oxford University Hospitals NHS Foundation Trust, Oxford
Quick Links:
Article
Article Information
Article:

BackgroundDelivery of cardiac resynchronisation therapy (CRT) using conventional systems can be limited by sub-optimal venous anatomy. The WiSE-CRT (EBR Systems, Sunnyvale, CA, USA) has been approved for use with existing right-sided systems. We report the case of a CRT recipient with a left ventricular (LV) lead in the middle cardiac vein (MCV) and who subsequently developed right ventricular (RV) lead failure.

ObjectiveTo describe the first-ever use of multisite LV pacing in a patient with the WiSE-CRT system.

Results: A 73-year old male with ischemic heart failure had received CRT-D using a bipolar LV lead in the MCV. The RV lead developed loss of sensing and capture 3 years on, leading to LV-only pacing. The patient deteriorated and echocardiography showed an LV ejection fraction (EF) of 17%. A venogram showed an occluded subclavian vein. Options were discussed and consent for a change to CRT-P combined with a WiSE-CRT implant was obtained. Day 1 involved the implant of the WiSE-CRT system transmitter under general anesthesia. The CRT-D generator was replaced with a CRT-P, the RV ICD lead pins were capped and both atrial and LV lead parameters were tested and satisfactory. On day 2, under conscious sedation, the receiver electrode was inserted using a retrograde transaortic approach and deployed on the endocardial aspect of the basal anterolateral LV wall. The existing LV lead was used to trigger the WiSE-CRT system, providing simultaneous LV and RV pacing. The AV delay was optimized to 150 ms to allow fusion with intrinsic cardiac conduction, with negative AV hysteresis programmed on (delta -20ms). The patient was seen in the research clinic 10 days and 6 months later, as per protocol. An acute QRS narrowing from 160ms (baseline) to 117ms (paced) was noted at implant. At 6 months, further improvement was noted with a QRS duration of 70ms; a reduction in LV end-systolic volume of 49%; an increase in EF to 41%; and an improvement in global longitudinal strain from -8.8% to -14.9%.

ConclusionThis report on the first-in-man use of fusion-based multisite LV pacing using a leadless endocardial pacing system demonstrates it is possible to synchronise the WiSE-CRT system with an LV lead, providing CRT to patients with sub-optimal coronary vein anatomy.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72